Can a common Anti-Inflammatory eye drop slow diabetic vision loss?

NCT ID NCT04505566

Completed Disease control Sponsor: Stephen J. Kim, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tests whether ketorolac, an anti-inflammatory eye drop, can reduce inflammation in the eyes of people with diabetic retinopathy and slow the disease. About 164 adults with type 2 diabetes will use either the active drop or a placebo for up to 3 years. Researchers will measure inflammatory markers and track changes in retinopathy severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ketorolac 0.45% ophthalmic solution (anti-inflammatory eye drop)
What this could lead to: If it works, this could point toward a simple eye drop treatment to slow vision loss from diabetic retinopathy.
What could go wrong: This is an early Phase 1 study with a small number of participants, so results may not apply broadly. The eye drops may not reduce inflammation enough to change disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic retinopathy type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC RETINOPATHY

Contacts and locations

Locations

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.